Alice T. Shaw, MD, PhD, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.
Alice T. Shaw, MD, PhD, an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital, discusses the results of a trial looking at LDK378 for patients with ALK+ crizotinib-resistant non-small cell lung cancer.
The results of the trial were remarkable, Shaw says, as nearly all patients in this population responded to LDK378.
In the case of EGFR-mutant lung cancer, there has been limited success once patients develop resistance to EGFR inhibitors. Because of this, it was unclear how successful ALK inhibitors would be in their respective space, but researchers were pleasantly surprised.
In the study, about 60% of patients responded, Shaw says. An additional 20-30% responded to treatment with LDK378, though formal criteria for a response was not met.
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More